«

»

Aug 23

We are encouraged very impressed by the results of our HD-02 study and we believe by Dr.

‘We are encouraged very impressed by the results of our HD-02 study and we believe by Dr.in conjunction with our colleagues at MGH, we have determined the optimal dose as we move us check on HD-02 as a potential treatment for Huntington’s disease, for which there is. No current drug approved by the FDA the development of therapeutics the development of therapeutics, that we can hope, are required to of neurodegenerative diseases of neurodegenerative diseases, ‘said Belinda Tsao – Nivaggioli, CEO of Avicena. We are of our studies of our studies with HD-02 to date this phase investigated III study whether -02-02 to slow the progression of Huntington’s disease and translate into real clinical benefit to patients, ‘said lead investigator Dr.

In in Manchester School of Translational Medicine, found that people who also meditate unusual activity showed during anticipation of pain in part of the prefrontal cortex, a brain region may be involved known in controlling attention and thought processes are perceived from potential threats.

About 35,000 people in the U.S. Suffer from Huntington’s disease , and an additional 150,000 Americans are carriers of the Huntington’s gene. Carriers of the Huntington’s gene will develop this deadly disease during their lifetime.. On HD-02HD-02 is a novel drug candidates for the treatment of Huntington’s disease with orphan drug designation in the U.S.Are cited among the current trends in the Tufts CSDD Outlook 2009 report, the following:Company globalization of preclinical and clinical development will overcome further local capacity constraints, increase speed to market, and expand its presence in emerging markets.continued lack of experienced personnel, especially among upper level executives, will continue the FDA ‘s ability to fulfill its mandate.

Outlook 2009 confirms more quickly FDA review New Drug Development still takes 8 years, depending on the tuft CSDD.

As the U.S. Food and Drug Administration accelerated drug review and registration of new drugs is to complex nature of diseases of to novel therapies be developed guided in longer clinical developing times, according to the Tufts Center for the Study of Drug Development.